Which is better, tremelimumab/tremelimumab or bevacizumab?

Tremelimumab/tremelimumab and bevacizumab (Bevacizumab) are two different drugs used for tumor treatment, with different mechanisms of action, approved indications and clinical trial use. The choice of use should be based on the patient's specific situation and the doctor's advice.

1. Mechanism of action: Tremelimumab is an immune checkpoint inhibitor that enhances immune response by inhibiting CTLA-4 (cytotoxic T lymphocyte-associated antigen-4). Bevacizumab is an angiogenesis inhibitor that inhibits tumor angiogenesis by targeting vascular endothelial growth factor (VEGF).

2. Indications: Tremelimumab is mainly used for the treatment of unresectable hepatocellular carcinoma and metastatic non-small cell lung cancer without sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor abnormalities. Bevacizumab is widely used in a variety of chemotherapy regimens for a variety of cancers to treat metastatic colorectal cancer, non-squamous non-small cell lung cancer, renal cell carcinoma, cervical cancer, etc.

3. Usage: Tremelimumab is administered via intravenous injection, usually every few weeks or once a month. Bevacizumab can be given by intravenous injection or subcutaneous injection, and the specific dosage and frequency of administration depend on the condition and your doctor's advice.

Tremelimumab/Tremelimumab is a new type of cancer immunotherapy drug. It has not yet been launched in China, so it cannot be included in the medical insurance. Domestic patients cannot yet purchase this drug. It is understood that the US version of temsitumumab original drug sold overseas may cost more than more than 3,000 US dollars per box, and the specification is 300mg/50mL (20mg/mL). The price is still relatively expensive. At present, we are not aware of the production and release of generic drugs of temsitumumab. For specific overseas prices and drug details, please consult Yaode Medical Consultants.